Bayer: Venous Thromboembolism trials

The registry lists 39 Venous Thromboembolism studies with Bayer as lead sponsor. 1 are open to participants now and 6 have results posted.

Phase 2 6Phase 3 10No phase 23(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE)Not yet recruitingNCT05900388
• EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous ThrombosisCompletedNCT02309411Phase 2Results posted
• EINSTEIN Junior: Oral Rivaroxaban in Children With Venous ThrombosisCompletedNCT02234843Phase 3Results posted
• Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)CompletedNCT02064439Phase 3Results posted
• Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill PatientsCompletedNCT00571649Phase 3Results posted
• Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension StudyCompletedNCT00439725Phase 3Results posted
• Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.CompletedNCT00362232Phase 3Results posted
• An Observational Study in the United States to Learn How Venous Thromboembolism, Disseminated Intravascular Coagulation, and Sepsis Are RelatedActive, not recruitingNCT06765681
• An Observational Study to Learn More About How Safe Treatment With Rivaroxaban is in Children in Japan With Venous ThromboembolismCompletedNCT06278051
• An Observational Study Called H2H-OSCAR-US to Learn More About How Well Rivaroxaban Works and How Safe it is Compared to Apixaban Under Real World Conditions in People in the US With Cancer Who Have Problems Due to Formation of Blood Clots in the Veins (Venous Thromboembolism)CompletedNCT05461807
• A Study to Gather Information About Rivaroxaban in Patients in Sweden With Cancer Who Also Have Thrombosis (OSCAR-SE)CompletedNCT05150938
• A Study to Gather Information About Rivaroxaban in Patients in the United Kingdom Who Have Cancer and Thrombosis (OSCAR-UK)CompletedNCT05112666
• Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States CohortCompletedNCT04979780
• A Study to Learn About Venous Thromboembolism (VTE) Treatment With Rivaroxaban in Japanese Patients Using a Claims DatabaseCompletedNCT04923139
• Study to Compare the Effectiveness of Rivaroxaban (Xarelto) Versus Low-molecular-weight Heparin (LMWH) and Phenprocoumon for the Treatment and Secondary Prevention of Venous Thromboembolism in Routine Clinical Practice in GermanyCompletedNCT04444804
• Study to Gather Information How Often Venous Thromboembolism Occurs in Prostate Cancer Patients in Sweden and How This Condition is Treated With Blood ThinnersCompletedNCT03965741
• An Observational Study on Incidence, Natural History and Treatment Patterns of Venous Thromboembolism in TaiwanCompletedNCT03799016
• Xarelto for Real Life Anticoagulation in Pulmonary Embolism (PE) in ChinaCompletedNCT03410706
• FactOr XIa inhibiTion for the pRevention of venOus Thromboembolism in Patients Undergoing Total Knee ArthroplastyCompletedNCT03276143Phase 2
• Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With RivaroxabanCompletedNCT03214172
• Verification of XAPPORT: a Decision Support App for Physicians Used for Patients Anticoagulated With Rivaroxaban in Terms of Anticoagulation Management in Elective Surgery: Verification Process of Medical Decision AlgorithmWithdrawnNCT02900404
• Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)CompletedNCT02558465
• Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)CompletedNCT02468102
• Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)CompletedNCT01947998
• Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)CompletedNCT01947985
• Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)CompletedNCT01947959
• Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care TherapyCompletedNCT01619007
• Study to Observe Safety of Xarelto in VTE Prophlylaxis After Elective TKR (Total Knee Replacement) or THR (Total Hip Replacement)WithdrawnNCT01523418
• Dose-confirmatory Bridging Study in Total Knee ReplacementCompletedNCT01206972Phase 3
• Dose-confirmatory Bridging Study in Total Hip ReplacementCompletedNCT01205932Phase 3
• Xarelto Regulatory Post-Marketing SurveillanceCompletedNCT01029743
• Xarelto for VTE Prophylaxis After Hip or Knee ArthroplastyCompletedNCT00831714
• An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging StudyCompletedNCT00402467Phase 2
• Dose-Ranging Study of BAY 59-7939 on the Prevention of VTE in Patients Undergoing Elective Total Hip ReplacementCompletedNCT00398905Phase 2
• Dose-ranging Study of Once-daily Regimen of BAY 59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip ReplacementCompletedNCT00396786Phase 2
• Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein ThrombosisCompletedNCT00395772Phase 2
• Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). A Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement.CompletedNCT00361894Phase 3
• Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, a Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip ReplacementCompletedNCT00332020Phase 3
• Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to EnoxaparinCompletedNCT00329628Phase 3